GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Junshi Biosciences Co Ltd (HKSE:01877) » Definitions » Financial Strength

Shanghai Junshi Biosciences Co (HKSE:01877) Financial Strength : 4 (As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Shanghai Junshi Biosciences Co Financial Strength?

Shanghai Junshi Biosciences Co has the Financial Strength Rank of 4.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is rated on a scale of 1 to 10 and is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.
4. Other debt related ratios.

A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

Shanghai Junshi Biosciences Co did not have earnings to cover the interest expense. Shanghai Junshi Biosciences Co's debt to revenue ratio for the quarter that ended in Dec. 2024 was 0.38. As of today, Shanghai Junshi Biosciences Co's Altman Z-Score is 1.89.


Competitive Comparison of Shanghai Junshi Biosciences Co's Financial Strength

For the Biotechnology subindustry, Shanghai Junshi Biosciences Co's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Junshi Biosciences Co's Financial Strength Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Junshi Biosciences Co's Financial Strength distribution charts can be found below:

* The bar in red indicates where Shanghai Junshi Biosciences Co's Financial Strength falls into.


;
;

Shanghai Junshi Biosciences Co Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Shanghai Junshi Biosciences Co's Interest Expense for the months ended in Dec. 2024 was HK$-47 Mil. Its Operating Income for the months ended in Dec. 2024 was HK$-390 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was HK$2,142 Mil.

Shanghai Junshi Biosciences Co's Interest Coverage for the quarter that ended in Dec. 2024 is

Shanghai Junshi Biosciences Co did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Shanghai Junshi Biosciences Co's Debt to Revenue Ratio for the quarter that ended in Dec. 2024 is

Debt to Revenue Ratio=Total Debt (Q: Dec. 2024 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(987.485 + 2141.743) / 8320.656
=0.38

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Shanghai Junshi Biosciences Co has a Z-score of 1.89, indicating it is in Grey Zones. This implies that Shanghai Junshi Biosciences Co is in some kind of financial stress. If it is below 1.81, the company may faces bankrupcy risk.

Warning Sign:

Altman Z-score of 1.89 is in the grey area. This implies that the company is under some kind of financial stress. If it is below 1.8, the company may face bankruptcy risk.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai Junshi Biosciences Co  (HKSE:01877) Financial Strength Explanation

The rank is rated on a scale of 1 to 10. A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

Shanghai Junshi Biosciences Co has the Financial Strength Rank of 4.


Shanghai Junshi Biosciences Co Financial Strength Related Terms

Thank you for viewing the detailed overview of Shanghai Junshi Biosciences Co's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Junshi Biosciences Co Business Description

Traded in Other Exchanges
Address
Nos. 36 and 58, Hai Qu Road, Room 1003, Level 10, Building 2, Pilot Free Trade Zone, Shanghai, CHN
Shanghai Junshi Biosciences Co Ltd is a China-based biotechnology companyy with all-round capabilities in innovative drug discovery and development, clinical research on a global scale, large-scale production capacity to commercialization on the full industry chain. Aiming to develop first-in-class or bestin-class drugs by way of original innovation and co-development. Companies operations are located in the PRC and the USA.
Executives
Gic (ventures) Pte. Ltd. 2201 Interest of corporation controlled by you
Gic Special Investments Private Limited 2102 Investment manager
Gic Private Limited 2201 Interest of corporation controlled by you
Highbury Investment Pte Ltd 2101 Beneficial owner
Jovial Champion Investments Limited 2201 Interest of corporation controlled by you
Gong Ruilin 2202 Interest of your spouse
Vistra Trust (singapore) Pte. Limited 2201 Interest of corporation controlled by you
Lvc Holdings Limited 2201 Interest of corporation controlled by you
Lvc Management Holdings Limited 2201 Interest of corporation controlled by you
Lvc Innovate Limited 2201 Interest of corporation controlled by you
Lin Lijun 2307 Founder of a discretionary trust who can infl
Lvc Renaissance Fund Lp 2101 Beneficial owner
Lvc Renaissance Limited 2201 Interest of corporation controlled by you
Loyal Valley Innovation Capital (hk) Limited 2201 Interest of corporation controlled by you
Lv Di Kong Gu Ji Tuan Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you

Shanghai Junshi Biosciences Co Headlines

No Headlines